
    
      PROTOCOL OUTLINE:

      Groups of 3 patients receive 1 of 4 doses of Ad5-CB-CFTR, a recombinant E1-deleted adenovirus
      serotype 5 vector containing the cystic fibrosis transmembrane conductance regulator gene.
      Ad5-CB-CFTR is administered to 1 nasal cavity and the vehicle alone is administered to the
      opposite nasal cavity as the control.
    
  